WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Technology Internet Technology Tuesday, October 23, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email


BDD Appoints Ex-AstraZeneca VP Joanne Kelley as Non-executive Director to the Board
Friday, October 12, 2018

GLASGOW, Scotland, October 12, 2018 /PRNewswire/ --

BDD today announced the appointment of Joanne Kelley as Non-executive Director of the Board.

Jo is a Life Sciences Business Development professional and brings an outstanding track record of strategy development, deal preparation and execution to the BDD Board.

During a long, successful career at AstraZeneca, Jo had extensive experience of global commercial and general management. In the role of Vice President of Business Development, Head of Transactions at AstraZeneca, Jo was responsible for a number of transformational deals. She has led all types of transactions including M&A, technology licensing and collaboration arrangements. Jo has received a number of awards recognising her deal making achievements from colleagues and peers including recognition from The Pharmaceutical Licensing Group.

After retiring from AstraZeneca Jo has continued to pursue her passion to support UK innovation. She now works as a Director of Alderley Park Ventures and is a non executive director at UMI3, the innovation company of Manchester University.

Commenting on this appointment, Howard Stevens, Chairman of BDD, said: "I am delighted to welcome Jo to the Board, she brings a broad range of experience to the role, including significant licensing experience. I am certain she will play a big part in BDD's future success as we continue to grow and expand our licensing and collaboration activities."

Commenting on her appointment, Jo said "I am delighted to be joining the Board of BDD at such an exciting time in the company's expansion. BDD is an innovative and ambitious company with a lot to offer pharma partners."

Notes to Editors 

About BDD 

BDD Pharma Ltd is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD's OralogiK(TM) technology is a tablet-in-tablet drug delivery system providing timed release, sustained release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK(TM) technology is protected with granted patents in the US, EU and Japan. Supported by investment from Archangels and the Scottish Investment Bank, BDD has in house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans.

For more information visit www.bddpharma.com. [http://www.bddpharma.com ]

SOURCE BDD Pharma Ltd



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Stratosphere Networks CISO Raises Funds for 2019 Mission Trip to Ecuador | Oct 23, 2018
Nav Standard Missile-2 defeats aerial targets in South Korean Navy exercises | Oct 23, 2018
Nav Raytheon's Rolling Airframe Missile to defend Armada de México patrol frigate | Oct 23, 2018
Nav Delta Care Rx Announces Launch of Virtual Assistant App for Hospice Clinicians | Oct 23, 2018
Nav Allot to Narrow the Technological Divide in Rural Territories With Improved Web Security and Network Performance | Oct 23, 2018
Nav ROAMING MAN Announces New G3 Wifi HotSpot On Sale | Oct 23, 2018
Nav Experian helps organizations maximize the potential of their data through the power of machine learning | Oct 23, 2018
Nav Geoswift Enables Customers to Scale Business Growth with Geoswift X, its new suite of Cross-Border Payment Solutions | Oct 23, 2018
Nav Oracle Cements Commitment to Next Generation of Enterprise Cloud | Oct 23, 2018
Nav TuneGO Inc. Names President of TuneGO China | Oct 23, 2018
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News